Skip to main content
SpringerLink
Log in

Equivalence and measurement properties of an electronic version of the Psoriasis Symptom Inventory

  • Published:
Quality of Life Research Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the equivalence of electronic and paper versions of the Psoriasis Symptom Inventory and to examine measurement properties of the electronic version.

Methods

In a prospective, randomized, crossover, non-interventional study in adult subjects (age ≥18 years) with plaque psoriasis conducted over a period of 15 days, subjects were randomized to two groups, completing either the paper or electronic Psoriasis Symptom Inventory daily for 7 consecutive days followed by the alternate version. Equivalence was assessed by the intraclass correlation coefficient (ICC) between both administration modes. Differences in scores were also tested using paired Student’s t test. Measurement properties included internal consistency reliability, test–retest reliability, and convergent and discriminant validity between the Psoriasis Symptom Inventory and (1) disease-specific (Dermatology Life Quality Index) and (2) general health (SF-36v2) status.

Results

Eighty subjects [74 % (59/80) moderate-to-severe psoriasis; 26 % (21/80) mild psoriasis receiving systemic treatment] were enrolled from 8 sites in the USA. The two modes were highly concordant for both total (ICC = 0.97) and individual item scores (ICC range = 0.93–0.97). Response bias testing showed no differences based on completion order with all ICC values >0.91. All mean score differences, except for one item (“flaking”), were non-significant (P > 0.05). Minimum values for reliability (>0.70) and validity (convergent, r ≥ 0.40) were exceeded for the electronic Psoriasis Symptom Inventory.

Conclusions

Equivalence between paper and electronic versions of the Psoriasis Symptom Inventory and strong measurement properties of the electronic mode indicated a successful migration from paper to electronic format of the Psoriasis Symptom Inventory.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. de Jong, E. M. G. J. (1997). The course of psoriasis. Clinics in Dermatology, 15(5), 687–692.

    Article  PubMed  Google Scholar 

  2. Martin, M. L., McCarrier, K., Bushnell, D. M., Gordon, K., Chiou, C.-F., Huang, X., Ortmeier, B., & Kricorian, G. (2011). Validation of the Psoriasis Symptom Inventory (PSI), a patient reported outcome measure. In 20th European academy of dermatology and venereology congress. Lisbon, Portugal.

  3. Martin, M. L., McCarrier, K., Bushnell, D. M., Gordon, K., Chiou, C.-F., Huang, X., et al. (2012). Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure. Journal of the American Academy of Dermatology, 66(4, Supplement 1), AB207.

    Google Scholar 

  4. Lui, H., & Mamelak, A. (2009). Plaque psoriasis. Updated: Sep 30, 2009. http://www.emedicine.com/derm/topic365.htm#section~clinical (see causes).

  5. Wilke, R., Burke, L., & Erickson, P. (2004). Measuring treatment impact: A review of patient reported outcomes and other efficacy endpoints in approved product labels. Controlled Clinical Trials, 26, 636–662.

    Google Scholar 

  6. Gwaltney, C. J., Shields, A. L., & Shiffman, S. (2008). Equivalence of electronic and paper-and-pencil administration of patient-reported outcome measures: A meta-analytic review. Value Health, 11(2), 322–333.

    Article  PubMed  Google Scholar 

  7. Stone, A. A., Shiffman, S., Schwartz, J. E., Broderick, J. E., & Hufford, M. R. (2002). Patient non-compliance with paper diaries. BMJ, 324(7347), 1193–1194.

    Article  PubMed Central  PubMed  Google Scholar 

  8. F. a. D. A. (FDA). (2009). Guidance for industry. Patient-reported outcome measures: Use in medical product development to support labeling claims. Retrieved December, 2009, 2009.

  9. Coons, S. J., Gwaltney, C. J., Hays, R. D., Lundy, J. J., Sloan, J. A., Revicki, D. A., et al. (2009). Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO good research practices task force report. Value Health, 12(4), 419–429.

    Article  PubMed  Google Scholar 

  10. Martin, M., Chen, T., Chau, D., & Viswanathan, H. (2012). Qualitative interviews with psoriasis patients evaluating paper to electronic migration of the Psoriasis Symptom Inventory (PSI). In Paper presented at the ISOQOL 2012. Budapest, Hungary.

  11. Martin, M., McCarrier, K., Chiou, C., Gordon, K., Kimball, A., Van Voorhees, A., Gottlieb, A., Huang, X., Globe, D., Chau, D., Viswanathan, H., & Kricorian, G. (2013). Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity. Journal of Dermatological Treatment, 24(4), 255–260.

    Google Scholar 

  12. Bushnell, D. M., Martin, M. L., McCarrier, K., Gordon, K., Chiou, C. F., Huang, X., Ortmeier, B., & Kricorian, G. (2013). Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity. Journal of Dermatological Treatment, 24(5), 356–360.

    Google Scholar 

  13. Revicki, D. A., Jin, Y., Chau, D., & Viswanathan, H. (2012). Reliability and validity of the Psoriasis Symptom Inventory in Patients with moderate to severe psoriasis. In International society for quality of life research 19th annual conference. Budapest.

  14. Revicki, D. A., Jin, Y., Wilson, H. D., Chau, D., & Viswanathan, H. N. (2013). Reliability and validity of the psoriasis symptom inventory in patients with moderate-to-severe psoriasis. Journal of Dermatological Treatment. doi:10.3109/09546634.2013.769042.

  15. Deyo, R. A., Diehr, P., & Patrick, D. L. (1991). Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Controlled Clinical Trials, 12(4 Suppl), 142S–158S.

    Article  CAS  PubMed  Google Scholar 

  16. Cronbach, L. (1951). Coefficient alpha and the internal structure of tests. Psychometrika, 16, 297–334.

    Article  Google Scholar 

  17. Lohr, K. (2002). Assessing health status and quality-of-life instruments: Attributes and review criteria. Quality of Life Research, 11(3), 193–205.

    Article  PubMed  Google Scholar 

  18. Nunnally, J., & Bernstein, I. (1994). Psychometric theory (3rd ed.). New York: McGraw-Hill.

    Google Scholar 

  19. Cohen, J. (1988). Statistical power analysis in the behavioral sciences (2nd ed.). Hillsdale, NJ: Lawrence Erlbaum Associates, Inc.

    Google Scholar 

  20. Bushnell, D. M., Reilly, M. C., Galani, C., Martin, M. L., Ricci, J. F., Patrick, D. L., et al. (2006). Validation of electronic data capture of the irritable bowel syndrome–quality of life measure, the work productivity and activity impairment questionnaire for irritable bowel syndrome and the EuroQol. Value Health, 9(2), 98–105.

    Article  PubMed  Google Scholar 

  21. Kvien, T. K., Mowinckel, P., Heiberg, T., Dammann, K. L., Dale, O., Aanerud, G. J., et al. (2005). Performance of health status measures with a pen based personal digital assistant. Annals of the Rheumatic Diseases, 64(10), 1480–1484.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Saleh, K. J., Radosevich, D. M., Kassim, R. A., Moussa, M., Dykes, D., Bottolfson, H., et al. (2002). Comparison of commonly used orthopaedic outcome measures using palm-top computers and paper surveys. Journal of Orthopaedic Research, 20(6), 1146–1151.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors wish to thank Jon Nilsen, PhD (Amgen Inc.) for providing writing support.

Conflict of interest

This study was funded by Amgen Inc. DMB, MLM, MS, and TCC are employees of Health Research Associates, Inc., which received funding for this study. DC and HV are employees and shareholders of Amgen Inc.

Author information

Authors and Affiliations

  1. Health Research Associates, Inc., 6505 216th St. SW, Suite 105, Mountlake Terrace, WA, 98043, USA

    Donald M. Bushnell, Mona L. Martin, Michael Scanlon & TeChieh Chen

  2. Amgen Inc, Thousand Oaks, CA, USA

    Dina Chau & Hema N. Viswanathan

Authors
  1. Donald M. Bushnell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mona L. Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Scanlon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. TeChieh Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dina Chau
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hema N. Viswanathan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Donald M. Bushnell.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bushnell, D.M., Martin, M.L., Scanlon, M. et al. Equivalence and measurement properties of an electronic version of the Psoriasis Symptom Inventory. Qual Life Res 23, 897–906 (2014). https://doi.org/10.1007/s11136-013-0527-1

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11136-013-0527-1

Keywords

Search

Navigation